Product Expansion BCR-ABL1 Control Panels launch expands product line into hematology and molecular monitoring. Target labs and researchers performing quantitative BCR-ABL1 assays and qPCR; opportunities to upsell QC materials and reference standards to accompany the new panels. Consider pilot deployments with academic labs, hospitals, and CROs to validate performance and capture early adopter feedback.

Liquid Biopsy QC Anchor Molecular focuses on high-quality QC and reference materials for cfDNA and ctDNA based tests, a growing segment in oncology diagnostics. There is a clear opportunity to offer end-to-end QC solutions for liquid biopsy workflows, including assay validation, lot consistency, and training support. Position as enabling reliable, reproducible liquid biopsy results at labs expanding in this space.

Channel Partnerships With a lean team and direct-to-lab sales model, the company can scale quickly through distributor or CRO partnerships. Identify regional distributors in key markets and offer bundled QC panels and reference materials with attractive terms. Co-marketing and joint business planning could accelerate adoption in mid-size labs that are underserved by larger vendors.

Regulatory Readiness Quality controls and reference materials are essential for regulatory compliance in molecular testing; Anchor Molecular can help labs meet validation and proficiency testing requirements. Emphasize reliability, traceability, and cost-effective solutions to attract labs seeking standardization as liquid biopsy adoption grows.

Digital Channel The ecommerce-centric tech stack enables a digital-first sales motion; there is an opportunity to optimize the online catalog, self-serve orders, and targeted campaigns. Leverage online analytics to identify high-potential lab segments and accelerate outreach for QC panels and cfDNA/ctDNA reference materials.